Internal Medicine - Hematology: Venous Thromboembolism; Anemia; Coagulopathy

Internal Medicine - Hematology: Venous Thromboembolism; Anemia; Coagulopathy is organized by American Medical Seminars (AMS), Inc.

Original Release Date: July 1, 2019
Expiration Date: July 1, 2022

Accreditation: 
• 5 AMA PRA Category 1 Credits™

Description:
Topic 1: Venous Thromboembolism (VTE): Diagnosis and Treatment.
Upon completion of this session, using the ACCP and ATS Guidelines and the Cochrane Abstract Database, the participant should be able to: COMP, GL, EBM
• Determine the diagnostic testing for evaluating a patient for possible VTE.
• Apply the algorithm for diagnosing a pulmonary embolism in multiple clinical settings.
• Differentiate the advantages and disadvantages of outpatient treatment compared to inpatient treatment for venous thromboembolism (VTE).
• Order the frequency of monitoring and the adjustments needed for warfarin therapy in the treatment of VTE.

Topic 2: Anemia.
Upon completion of this session, the participant should be able to: COMP, GL
• Develop a diagnostic strategy to ascertain the etiology of the anemia.
• Utilize the guidelines for diagnosing anemia in children and adults in terms of available testing.
• Develop a clinical approach to treating various anemias to include Iron Deficiency and “Anemia of Chronic Disease” due to infections, inflammatory dz’s, CKD, Malignancies, Cytokines, Interferons, TNF’s, etc.
• Describe the role of consultants in the evaluation and management of anemia.

Topic 3: Coagulopathy in the ER: All Bleeding Stops Eventually.
Upon completion of this session, the participant should be able to: COMP, EBM
• Differentiate different patterns of coagulopathy that present to the ED.
• Develop an evaluation and treatment plan for non-traumatic bleeding disorders in the ED, including hemophilia, TTP, ITP and others.
• Outline the rationale and indications for the use of blood products used in the treatment of the bleeding patient.
• Discuss some of the newer anticoagulation agents used today, such as Prasugrel (Effient) and Dabigatran (Pradaxa), as per thr referenced RCT’s and EBM studies such as Rocket, RE-LY and Einstein.